Gu, Sophie Z.
Nanegrungsunk, Onnisa
Bressler, Susan B.
Du, Weiming
Amer, Fouad
Moini, Hadi
Bressler, Neil M.
Funding for this research was provided by:
Regeneron Pharmaceuticals
Department of Surgery, School of Medicine, Johns Hopkins University
Article History
Received: 31 March 2022
Revised: 31 March 2022
Accepted: 14 May 2022
First Online: 24 June 2022
Declarations
:
: The COPERNICUS, GALILEO, and VIBRANT clinical trials were conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization guidelines. The protocol for each trial was approved by the independent ethics committee or institutional review board at each study site.
: Informed consent was obtained from all individual participants included in the COPERNICUS, GALILEO, and VIBRANT clinical trials.
: SZG, none; ON, none; SBB, grants to Johns Hopkins University School of Medicine from Amgen, Bayer, Biocon, Biogen, Boehringer-Ingleheim Pharma GmbH & Co., Genentech (Roche), Eyepoint, Mylan Inc, Notal Vision, Novartis, and Regeneron; WD, employment with and stock ownership in Regeneron Pharmaceuticals, Inc.; FA, employment with and stock ownership in Regeneron Pharmaceuticals, Inc.; HM, employment with and stock ownership in Regeneron Pharmaceuticals, Inc.; NMB, grants to Johns Hopkins University from Bayer, Biogen, Genentech (Roche), Novartis, Regeneron, and Samsung Bioepis and contract with AMA as Editor in Chief of <i>JAMA Ophthalmology</i>.